Drugs Containing Excipient (Inactive Ingredient) BANANA

Branded drugs containing BANANA excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	BANANA
SCILEX PHARMACEUTICALS INC	ELYXYB - CELECOXIB	celecoxib	69557-333	BANANA

Generic drugs containing BANANA excipient

Company	Ingredient	NDC	Excipient
Xttrium Laboratories Inc	nystatin	0116-4026	BANANA
Pharmaceutical Associates Inc	abacavir	0121-0897	BANANA
Par Pharmaceutical Inc	erythromycin ethylsuccinate	0254-1020	BANANA
Lannett Company Inc	famotidine	0527-5190	BANANA
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	acyclovir	23155-485	BANANA
PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS	azithromycin	24658-706	BANANA
Camber Pharmaceuticals Inc	famotidine	31722-063	BANANA

Last updated: July 19, 2026

Market Dynamics and Financial Trajectory for the Pharmaceutical Excipient “BANANA”

Executive summary: “BANANA” is not a defined pharmaceutical excipient name used in regulatory compendia or common excipient catalogs, and there is no traceable drug master data, FDA/EMA listing, manufacturer attribution, or market sizing tied to a distinct, legally defined excipient under that label. As a result, market dynamics and a financial trajectory cannot be produced in a way that is accurate and decision-grade.

If “BANANA” is intended to refer to a specific excipient trade name, chemical identifier, or specific ingredient (eg, excipient functional class such as binder, filler, disintegrant, surfactant, plasticizer; or a specific ingredient like “amyl acetate,” “banana flavor,” “ethyl butyrate,” etc.), the label must map to a unique substance and supply chain participant to support any of the following: (i) regulatory status (FDA inactive ingredient database, EMA excipient register), (ii) competitive landscape (global and regional producers), (iii) demand drivers (dosage forms, biologics vs small molecule mix, tablet/capsule vs oral liquid), (iv) pricing and margin analysis (raw material index linkage, contract pricing, freight/energy effects), or (v) financial trajectory (revenue pools, capex cycle, volume growth, and working-capital sensitivity).

Market dynamics, financial trajectory, and revenue exposure require substance-level identification. Without that mapping, any figures or “who wins/loses” conclusions would be non-falsifiable and unusable for R&D, licensing, litigation, or investment decisions.

Key takeaways

• No defensible market-sizing or financial trajectory can be generated for “BANANA” without a unique substance mapping.
• Decision-grade excipient analysis depends on regulatory identity, manufacturing footprint, and supply chain traceability.
• A substantiated answer requires “BANANA” to correspond to a specific excipient with a stable INCI/USP/NF/E-number/CAS and clear FDA/EMA status.

FAQs

1. What regulatory databases list pharmaceutical excipients by name?
2. How do excipient market dynamics typically track with dosage form mix?
3. Which excipient price drivers are most sensitive to energy and freight cycles?
4. How do inactive ingredient and excipient monograph statuses affect sourcing risk?
5. What margin structure is typical for excipient producers (raw material pass-through vs specialty pricing)?

References

No sources were cited because “BANANA” could not be mapped to a uniquely identifiable excipient substance in the available information.